MX2021004860A - Piridazinas novedosas. - Google Patents

Piridazinas novedosas.

Info

Publication number
MX2021004860A
MX2021004860A MX2021004860A MX2021004860A MX2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A
Authority
MX
Mexico
Prior art keywords
pyridazines
novel
novel pyridazines
autotaxin
therapy
Prior art date
Application number
MX2021004860A
Other languages
English (en)
Inventor
Gerald Juergen Roth
Christian Andreas Kuttruff
Tom Bretschneider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021004860A publication Critical patent/MX2021004860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a piridazinas novedosas, procesos para su preparación, composiciones farmacéuticas que las contienen y su uso en los tratamientos, en particular, en el tratamiento y/o la prevención de enfermedades y trastornos mediados por autotaxina.
MX2021004860A 2018-10-29 2019-10-25 Piridazinas novedosas. MX2021004860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203226 2018-10-29
PCT/EP2019/079231 WO2020089098A1 (en) 2018-10-29 2019-10-25 Novel pyridazines

Publications (1)

Publication Number Publication Date
MX2021004860A true MX2021004860A (es) 2021-06-15

Family

ID=64048690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004860A MX2021004860A (es) 2018-10-29 2019-10-25 Piridazinas novedosas.

Country Status (19)

Country Link
US (1) US11104665B2 (es)
EP (1) EP3873472B1 (es)
JP (1) JP7214860B2 (es)
KR (1) KR20210084597A (es)
CN (1) CN112996513A (es)
AR (1) AR116877A1 (es)
AU (1) AU2019373324A1 (es)
BR (1) BR112021005445A2 (es)
CA (1) CA3113712A1 (es)
CL (1) CL2021000930A1 (es)
DK (1) DK3873472T3 (es)
EA (1) EA202191115A1 (es)
ES (1) ES2955723T3 (es)
HU (1) HUE063845T2 (es)
IL (1) IL282425B1 (es)
MX (1) MX2021004860A (es)
PL (1) PL3873472T3 (es)
TW (1) TW202035374A (es)
WO (1) WO2020089098A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220035950A (ko) * 2019-07-22 2022-03-22 베링거 인겔하임 인터내셔날 게엠베하 염증성 기도 질환 또는 섬유성 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 n-메틸, n-(6-(메톡시)피리다진-3-일) 아민 유도체
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
EP3760630A1 (en) 2013-03-14 2021-01-06 Galapagos N.V. Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014202458A1 (en) 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9604974B2 (en) * 2015-01-22 2017-03-28 University Of Mysore Compounds as modulator of JAK-STAT pathway, methods and applications thereof
KR20220035950A (ko) 2019-07-22 2022-03-22 베링거 인겔하임 인터내셔날 게엠베하 염증성 기도 질환 또는 섬유성 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 n-메틸, n-(6-(메톡시)피리다진-3-일) 아민 유도체
US11485727B2 (en) 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines

Also Published As

Publication number Publication date
CL2021000930A1 (es) 2021-11-12
CA3113712A1 (en) 2020-05-07
EP3873472A1 (en) 2021-09-08
AU2019373324A1 (en) 2021-04-22
DK3873472T3 (da) 2023-09-04
IL282425A (en) 2021-06-30
IL282425B1 (en) 2024-03-01
JP2022506046A (ja) 2022-01-17
JP7214860B2 (ja) 2023-01-30
HUE063845T2 (hu) 2024-02-28
TW202035374A (zh) 2020-10-01
ES2955723T3 (es) 2023-12-05
US20200131151A1 (en) 2020-04-30
PL3873472T3 (pl) 2023-12-27
US11104665B2 (en) 2021-08-31
EA202191115A1 (ru) 2021-09-06
BR112021005445A2 (pt) 2021-06-15
KR20210084597A (ko) 2021-07-07
EP3873472B1 (en) 2023-07-12
AR116877A1 (es) 2021-06-23
WO2020089098A1 (en) 2020-05-07
CN112996513A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2021009673A (es) Moduladores de ror-gamma.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
PH12021550872A1 (en) Therapeutic compounds
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
MX2021004860A (es) Piridazinas novedosas.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MY201535A (en) Therapeutic compounds
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
WO2017168454A3 (en) Novel compounds as btk inhibitors